The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

Haematologica

Volumn 97, Issue 11, 2012, Pages 1722-1730

  Zauli, Giorgio ^a   Celeghini, Claudio ^b   Melloni, Elisabetta ^c   Voltan, Rebecca ^c   Ongari, Manuele ^d   Tiribelli, Mario ^e   di Iasio, Maria Grazia ^c   Lanza, Francesco ^d   Secchiero, Paola ^c  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d CREMONA HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Acute myeloid leukemia; Apoptosis; Autophagy; Nutlin 3; P53; Sorafenib

Indexed keywords

CD135 ANTIGEN; MESSENGER RNA; NUTLIN 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOLYSOSOME; AUTOPHAGY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; FEMALE; FMS-LIKE TYROSINE KINASE 3; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868598894     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.062083     Document Type: Article

References (40)

1. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, et al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810-6.
2. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008; 100(3):184-98.
3. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007;92(1):27-34.
4. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62-8.
5. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009; 113(15):6567-71.
6. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, et al. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation. Blood. 2012;119 (22):5133-43.
7. Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bimdependent process. Blood. 2012;119(25): 6089-98.
8. Secchiero P, di Iasio MG, Gonelli A, Zauli G. The MDM2 inhibitors Nutlins as an innovative therapeutic tool for the treatment of hematological malignancies. Curr Pharmac Des. 2008;14(21):2100-10.
9. Mitani N, Niwa Y, Okamoto Y. Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007;44(Pt6):557-9.
10. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106 (9):3150-9.
11. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab. 2007;8(4):395-403.
12. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood. 2010;116(1):71-80.
13. Wergeland L, Sjøholt G, Haaland I, Hovland R, Bruserud Ø, Gjertsen BT. Preapoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer. 2007;6:33.
14. Campioni D, Corallini A, Zauli G, Possati L, Altavilla G, Barbanti-Brodano G. HIV type 1 extracellular tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res Human Retroviruses. 1995;11(9):1039-48.
15. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005;166(2):557-63.
16. Zauli G, Visani G, Bassini A, Caramelli E, Ottaviani E, Bertolaso L, et al. Nuclear translocation of protein kinase C-alpha and-zeta isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. Br J Haematol. 1996;93(3):542-50.
17. Gibellini D, Bassini A, Pierpaoli S, Bertolaso L, Milani D, Capitani S, et al. Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol. 1998;160(8):3891-8.
18. Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood. 2007; 109(9):4006-15.
19. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
20. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(22):1982-96.
21. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11(15):5472-80.
22. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007; 12(4):426-37.
23. Vatsyayan R, Singhal J, Nagaprashantha LD, Awasthi S, Singhal SS. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog. 2011 Oct 17. doi: 10.1002/mc.20875. [Epub ahead of print]
24. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5(9):726-34.
25. Germain M, Slack RS. Mcl-1 regulates the balance between autophagy and apoptosis. Autophagy. 2011;7(5):549-51.
26. Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multikinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol. 2012;157(4):510-4.
27. Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarget. 2011;2(3):239-44.
28. van Stijn A, van der Pol MA, Kok A, Bontje PM, Roemen GM, Beelen RH, et al. Differences between the CD34+ and CD34-blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica. 2003;88(5):497-508.
29. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114(24):5034-43.
30. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia. 1997;11(10):1605-9.
31. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000;7(12):1166-73.
32. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17(14):3878-85.
33. Dice JF. Chaperone-mediated autophagy. Autophagy. 2007;3(4):295-9.
34. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132 (1):27-42.
35. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720-8.
36. Park MA, Reinehr R, Hussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010;9(8):2220-31.
37. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAKdependent autophagy. Cancer Biol Ther. 2009;8(21):2084-96.
38. Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther. 2008;7(2):297-313.
39. Jin L, Tabe Y, Kojima K, Zhou Y, Pittalunga S, Konopleva M, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299(2):161-70.
40. Ha JH, Won EY, Shin JS, Jang M, Ryu KS, Bae KH, et al. Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins. J Am Chem Soc. 2011;133(5):1244-7.